FDA – Page 75 – Pharma.Tips

Packaging compatibility risk during inspection readiness – regulatory risk analysis and mitigation

Assessing Packaging Compatibility Risks During Inspection Readiness and Mitigating Regulatory Issues Pharmaceutical packaging plays a crucial role in maintaining product integrity and compliance with regulatory standards. However, risks associated with…

Interface validation gaps during data integrity review – FDA/EMA expectations for computerized systems

“`html Addressing Gaps in Interface Validation during Data Integrity Review: A Structured Investigation In the fast-paced world of pharmaceutical manufacturing, ensuring data integrity is paramount. Interface validation gaps can lead…

Extractables and leachables concern during supplier change – inspection evidence expectations

Investigating Extractables and Leachables Concerns During Supplier Changes: Evidence Expectations Extractables and leachables (E&L) represent a critical concern during the supplier change process in pharmaceutical manufacturing. These substances can potentially…

CSV not aligned to actual use during system operation – inspection evidence pack preparation

Examining the Misalignment of CSV with Operational Practices in Pharmaceutical Systems In the pharmaceutical industry, ensuring that computer system validation (CSV) aligns with actual operational use is paramount for maintaining…

Artwork change error during supplier change – documentation gaps regulators question

Analyzing Artwork Change Errors During Supplier Transitions and Addressing Documentation Gaps Comprehensively In the dynamic environment of pharmaceutical operations, the accuracy and compliance of artwork changes are critical, particularly during…

Patch management weaknesses during validation lifecycle – FDA/EMA expectations for computerized systems

Understanding Patch Management Weaknesses in the Validation Lifecycle: FDA and EMA Considerations In a highly regulated industry like pharmaceuticals, ensuring that computerized systems remain compliant throughout their lifecycle is paramount.…

Packaging compatibility risk during scale-up – CAPA and control strategy

“`html Understanding and Managing Packaging Compatibility Risks During Scale-Up In pharmaceutical manufacturing, the scale-up phase can introduce various risks, particularly regarding packaging compatibility. As processes shift from development to larger…

Audit trail gaps identified during system upgrades – FDA/EMA expectations for computerized systems

Understanding Audit Trail Gaps During System Upgrades in GMP Compliance In the fast-paced world of pharmaceutical manufacturing, maintaining compliance during system upgrades is critical. Audit trail gaps identified during system…

Artwork change error during inspection readiness – how to prevent recall triggers

“` Understanding Artwork Change Errors During Inspection Readiness: A Practical Investigation Guide In the highly regulated pharmaceutical sector, packaging errors, particularly those related to artwork changes, can trigger significant compliance…

System access control failure during system upgrades – inspection evidence pack preparation

Addressing System Access Control Failures During System Upgrades: An Investigation Framework In pharmaceutical manufacturing, the integrity of data and systems is paramount, particularly during system upgrades. A common issue that…

Artwork change error during scale-up – inspection evidence expectations

Addressing Artwork Change Errors during Scale-Up: Ensuring Regulatory Compliance Artwork change errors during the scale-up process in pharmaceutical operations pose significant risks to product quality, regulatory compliance, and patient safety.…

Case processing backlog during signal review – regulatory enforcement risk and mitigation

Managing Case Processing Backlogs in Signal Review: Investigation and Mitigation Strategies In the pharmaceutical industry, the ability to effectively process adverse event cases during signal review is critical to ensuring…